Aaron Tachibana Sells 38,799 Shares of Personalis (NASDAQ:PSNL) Stock

Personalis, Inc. (NASDAQ:PSNL) CFO Aaron Tachibana sold 38,799 shares of the company’s stock in a transaction that occurred on Friday, May 29th. The stock was sold at an average price of $11.58, for a total transaction of $449,292.42. Following the completion of the transaction, the chief financial officer owned 198,833 shares in the company, valued at approximately $2,302,486.14. This represents a 16.33% decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Personalis Stock Up 3.8%

Shares of NASDAQ PSNL traded up $0.42 during midday trading on Friday, hitting $11.40. The stock had a trading volume of 4,471,474 shares, compared to its average volume of 2,505,722. The business’s 50 day moving average is $6.86 and its 200-day moving average is $8.10. The company has a market cap of $1.19 billion, a P/E ratio of -11.18 and a beta of 1.96. Personalis, Inc. has a 52 week low of $3.84 and a 52 week high of $11.85.

Personalis (NASDAQ:PSNL) last issued its earnings results on Thursday, May 7th. The company reported ($0.29) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.23) by ($0.06). The firm had revenue of $15.47 million during the quarter, compared to the consensus estimate of $14.49 million. Personalis had a negative return on equity of 43.52% and a negative net margin of 148.11%. As a group, analysts expect that Personalis, Inc. will post -1.06 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

PSNL has been the topic of several analyst reports. Wall Street Zen downgraded shares of Personalis from a “hold” rating to a “sell” rating in a research note on Saturday, May 9th. Needham & Company LLC upped their target price on shares of Personalis from $10.00 to $12.00 and gave the stock a “buy” rating in a research note on Friday, February 27th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Personalis in a research note on Tuesday, April 21st. BTIG Research dropped their target price on shares of Personalis from $13.00 to $11.00 and set a “buy” rating on the stock in a research note on Monday, May 11th. Finally, Morgan Stanley lowered their price objective on shares of Personalis from $10.00 to $9.00 and set an “equal weight” rating on the stock in a research report on Tuesday, May 12th. Five investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $11.00.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Bank of America Corp DE lifted its position in Personalis by 85.4% during the first quarter. Bank of America Corp DE now owns 111,306 shares of the company’s stock valued at $709,000 after purchasing an additional 51,273 shares during the period. Janus Henderson Group PLC bought a new position in Personalis during the first quarter valued at approximately $192,000. ADAR1 Capital Management LLC bought a new position in Personalis during the first quarter valued at approximately $159,000. Sei Investments Co. lifted its position in Personalis by 148.3% during the first quarter. Sei Investments Co. now owns 139,046 shares of the company’s stock valued at $886,000 after purchasing an additional 83,040 shares during the period. Finally, Dimensional Fund Advisors LP lifted its position in Personalis by 8.4% during the first quarter. Dimensional Fund Advisors LP now owns 1,066,248 shares of the company’s stock valued at $6,791,000 after purchasing an additional 83,074 shares during the period. Institutional investors own 61.91% of the company’s stock.

Personalis Company Profile

Personalis, Inc (NASDAQ: PSNL) is a clinical‐stage genomics company that develops and markets advanced next‐generation sequencing (NGS) services and assays designed to accelerate precision medicine. The Company’s core offering is the ImmunoID NeXT™ Platform, which combines comprehensive tumor profiling—including whole exome, transcriptome, and T‐cell receptor sequencing—with proprietary bioinformatics to identify biomarkers and guide immuno‐oncology research. Personalis serves biopharmaceutical companies, academic institutions, and clinical research organizations seeking in‐depth insights into cancer, autoimmune diseases and other complex conditions.

In addition to its flagship ImmunoID NeXT™ Platform, Personalis offers a suite of customizable sequencing assays for biomarker discovery, clinical trial support and companion diagnostic development.